0001062993-24-010179.txt : 20240514
0001062993-24-010179.hdr.sgml : 20240514
20240514163224
ACCESSION NUMBER: 0001062993-24-010179
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240510
FILED AS OF DATE: 20240514
DATE AS OF CHANGE: 20240514
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Frieberg Jacob B.
CENTRAL INDEX KEY: 0001748346
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38624
FILM NUMBER: 24944985
MAIL ADDRESS:
STREET 1: 1895 MOUNT HOPE AVENUE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VACCINEX, INC.
CENTRAL INDEX KEY: 0001205922
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 161603202
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1895 MOUNT HOPE AVE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
BUSINESS PHONE: 585-271-2700
MAIL ADDRESS:
STREET 1: 1895 MOUNT HOPE AVE
CITY: ROCHESTER
STATE: NY
ZIP: 14620
FORMER COMPANY:
FORMER CONFORMED NAME: VACCINEX INC
DATE OF NAME CHANGE: 20021114
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-05-10
0001205922
VACCINEX, INC.
VCNX
0001748346
Frieberg Jacob B.
C/O VACCINEX, INC.
1895 MOUNT HOPE AVENUE
ROCHESTER
NY
14620
1
0
0
0
0
Common Stock
303
D
Common Stock
451
I
By Benbow Estates, Ltd.
Common Stock
920
I
By Gee Eff Services Limited
Stock Option (Right to Buy)
2856.0
2027-09-15
Common Stock
30
30
D
Stock Option (Right to Buy)
1104.6
2029-03-30
Common Stock
11
11
D
Stock Option (Right to Buy)
1633.8
Common Stock
36
36
D
Stock Option (Right to Buy)
1159.2
2029-06-29
Common Stock
11
11
D
Stock Option (Right to Buy)
1505.7
2029-09-27
Common Stock
8
8
D
Stock Option (Right to Buy)
1018.5
2029-12-28
Common Stock
13
13
D
Stock Option (Right to Buy)
840.0
2030-03-29
Common Stock
15
15
D
Stock Option (Right to Buy)
829.5
Common Stock
74
74
D
Stock Option (Right to Buy)
758.1
2030-06-28
Common Stock
17
17
D
Stock Option (Right to Buy)
373.8
2030-09-28
Common Stock
36
36
D
Stock Option (Right to Buy)
434.7
2030-12-29
Common Stock
31
31
D
Stock Option (Right to Buy)
625.8
2031-03-31
Common Stock
21
21
D
Stock Option (Right to Buy)
451.5
Common Stock
136
136
D
Stock Option (Right to Buy)
588.0
2031-06-28
Common Stock
22
22
D
Stock Option (Right to Buy)
453.6
2031-09-28
Common Stock
29
29
D
Stock Option (Right to Buy)
218.4
2031-12-29
Common Stock
61
61
D
Stock Option (Right to Buy)
277.2
2032-03-28
Common Stock
47
47
D
Stock Option (Right to Buy)
235.2
Common Stock
253
253
D
Stock Option (Right to Buy)
226.8
2032-06-27
Common Stock
57
57
D
Stock Option (Right to Buy)
104.02
2032-09-27
Common Stock
125
125
D
Stock Option (Right to Buy)
135.52
2032-12-28
Common Stock
94
94
D
Stock Option (Right to Buy)
83.86
2033-03-28
Common Stock
152
152
D
Stock Option (Right to Buy)
86.1
Common Stock
684
684
D
Stock Option (Right to Buy)
74.76
2033-06-27
Common Stock
172
172
D
Stock Option (Right to Buy)
5.75
2024-05-10
4
A
0
2211
3.96
A
2024-05-10
2034-05-10
Common Stock
2211
2211
D
Stock Option (Right to Buy)
5.75
2024-05-10
4
A
0
10108
0
A
2025-05-10
Common Stock
10108
10108
D
Mr. Frieberg's spouse is the owner of Benbow Estates, Ltd. and Mr. Frieberg is an officer of Benbow Estates, Ltd. Mr. Frieberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Mr. Frieberg is the sole owner and President of Gee Eff Services Limited.
Exercisable in full as of the date of this report.
This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.
This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.
Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the first quarter of 2024. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable.
This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.
On February 19, 2024, Vaccinex, Inc. effected a 1-for-14 reverse stock split (the "Reverse Stock Split"). The number of stock options and underlying shares of common stock in this Form 4 reflect the Reverse Stock Split.
/s/ Maurice Zauderer, Attorney-in-Fact for Jacob Frieberg
2024-05-14